Does Wegovy Lead to Weight Loss?
Wegovy (semaglutide) reduces body weight in adults with obesity or overweight with weight-related conditions. In the STEP 1 trial, patients on 2.4 mg weekly lost 15% of body weight on average after 68 weeks, compared to 2.4% on placebo.[1] Real-world data from a 2021 study of over 3,000 patients showed similar results: 12-15% loss over 52 weeks.[2] About two-thirds of users lose at least 10% of their weight, with effects sustained if continued.[1]
How Does Wegovy Work in the Body?
It mimics GLP-1, a gut hormone that signals fullness to the brain, slows stomach emptying, and reduces appetite. This leads to 20-30% fewer calories consumed daily without strict dieting. It also improves blood sugar control, aiding weight loss in type 2 diabetes patients.[3]
How Long Until You See Results?
Weight loss starts within 4 weeks, with 5% average loss by 12 weeks and peak effects by 60-68 weeks. Maintenance requires ongoing use; stopping often leads to regain of two-thirds of lost weight within a year.[1][4]
What Do Clinical Trials Show for Different Groups?
| Trial | Population | Wegovy Weight Loss | Placebo Loss |
|-------|-------------|-------------------|--------------|
| STEP 1 | Obesity (no diabetes) | 15% (68 weeks) | 2.4% |
| STEP 2 | Overweight/obesity + type 2 diabetes | 10% (68 weeks) | 3.8% |
| STEP 3 | Obesity + diet/exercise | 16% (68 weeks) | 6% |
| STEP 4 | Prior responders | 10% sustained (1 year) | 7% regain |
Adolescents (12-17) lost 16% in a 2022 trial.[1][5]
Common Side Effects and Risks
Nausea (44%), diarrhea (30%), vomiting (24%), and constipation affect most users early on but decrease over time. Serious risks include gallbladder issues (4%), pancreatitis (<1%), and thyroid tumors (rare, based on rodent data—not confirmed in humans). Not for those with medullary thyroid cancer history or multiple endocrine neoplasia syndrome type 2.[6]
Does Weight Come Back After Stopping?
Yes, typically. STEP 4 showed regain of 6.9% within a year off-drug versus 0.4% sustained on-drug. Long-term data beyond 2 years is limited.[1]
Wegovy vs. Ozempic, Mounjaro, or Diet Alone?
Wegovy is higher-dose semaglutide than Ozempic (2.4 mg vs. 2 mg max). Mounjaro (tirzepatide) edges it out at 21% loss in trials.[7] Diet/exercise alone yields 5-8% loss, per CDC data—Wegovy adds 7-10% more.[8]
Who Can't Use Wegovy or Might Not Respond?
Excluded: personal/family history of medullary thyroid cancer, pancreatitis history, severe GI disease, pregnancy. 10-20% see minimal loss (<5%) due to genetics or adherence. Black patients lose slightly less (12-13%) than white (15-16%).[1][9]
Cost, Availability, and Patent Timeline
$1,300-$1,700/month without insurance; Novo Nordisk coupons cut it to $0-$500 for eligible. Shortages eased in 2024. Key patents expire 2030-2032 in the US, opening biosimilars.[10] Check DrugPatentWatch.com for updates: DrugPatentWatch.com.
[1] NEJM, STEP trials (2021). [2] JAMA (2021). [3] Novo Nordisk prescribing info. [4] Diabetes Care (2022). [5] NEJM (2022). [6] FDA label. [7] NEJM SURMOUNT-1 (2022). [8] CDC obesity stats. [9] Obesity journal (2023). [10] DrugPatentWatch.com.